Ingrese al sitio (login)

Por tareas de mantenimiento, hemos suspendido nuevas suscripciones al sitio.



>>> IMPORTANTE: los datos y consultas de los usuarios registrados, se mantienen bajo estricta confidencialidad. <<<

Buscar...

mens sana in corpore sano...

endocrinología | metabolismo | nutrición

Tratamiento con romosozumab para pacientes en posmenopausia

Escrito por Sugerido por la Dra. Susana Scarone
PDFImprimirCorreo electrónico
01
Abr
2019

unnamed

FDA Approves Romosozumab For Treatment Of Osteoporosis After Menopause.

The New York Times (4/9, Kolata) reports that on April 9, the Food and Drug Administration approved Evenity (romosozumab), “an osteoporosis drug that represents the first new treatment approach in nearly two decades – a strategy based on a rare gene mutation in people with bones so dense that they never break.” The drug is intended for postmenopausal women who are at high risk for a bone fracture. Nevertheless, the agency “said it was requiring the boxed warning on the drug’s label saying the drug should not be used by people who had a heart attack or stroke in the past year.”

        Reuters (4/9, Mishra, Joseph) reports, “The decision comes months after an FDA panel overwhelmingly voted for the drug’s approval.” The newly approved drug belongs to a “new class” of medications “known as sclerostin inhibitors,” and “is administered with two 105 mg injections every month for a year, followed by chronic therapy with an antiresorptive drug.”

        Also covering the story are MedPage Today (4/9), HealthDay (4/9, Mundell), and Medscape (4/9, Brooks, Subscription Publication).

 

Material compartido en la newsletter de la Endocrine Society

Última actualización el 10 de Abril de 2019
separator copy.jpg
separator copy.jpg
Buscar - Contenidos
Buscar - Weblinks
Buscar - Contactos
Buscar - Categorias
Buscar - Secciones
Buscar - Newsfeeds
separator copy.jpg
separator copy.jpg
separator copy.jpg